

Research Letter



Changes in Risk Factor Status and Risk of Future ASCVD Events in Primary Prevention

In-Chang Hwang , MD^{1,2}, Chee Hae Kim , MD³, Jae Young Kim , MS⁴, Jiesuck Park , MD¹, Hye Jung Choi , MD¹, Hong-Mi Choi , MD^{1,2}, Yeonyee E. Yoon , MD, PhD^{1,2}, and Goo-Yeong Cho , MD, PhD^{1,2}

¹Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

²Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

³Veteran Health Service Medical Center, Seoul, Korea

⁴Department of Statistics, Soonchunhyang University Bucheon Hospital, Bucheon, Korea



Received: Jan 8, 2024

Revised: Feb 26, 2024

Accepted: Apr 4, 2024

Published online: Apr 11, 2024

Correspondence to

In-Chang Hwang, MD

Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea.
Email: inchang.hwang@gmail.com

Copyright © 2024. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


ORCID iDs

In-Chang Hwang 

<https://orcid.org/0000-0003-4966-3924>

Chee Hae Kim 


<https://orcid.org/0000-0002-7767-9395>

Jae Young Kim 


<https://orcid.org/0000-0001-9628-421X>

Jiesuck Park 


<https://orcid.org/0000-0001-6924-7106>

Hye Jung Choi 

<https://orcid.org/0000-0002-3157-0247>

Hong-Mi Choi 

<https://orcid.org/0000-0002-6856-2486>

Yeonyee E. Yoon 

<https://orcid.org/0000-0002-8479-9889>

In clinical practice, primary prevention targets cardiovascular risk factors through lifestyle changes and therapeutic interventions, which can alter risk factor status over time and affect prognosis.¹⁾ While prior studies typically assessed risk factors only at baseline, neglecting temporal changes,^{2,3)} our recent publication demonstrated a significant correlation between the rate of change in 10-year atherosclerotic cardiovascular disease (ASCVD) risk (Δ 10-year ASCVD risk/year) and future ASCVD events, irrespective of baseline risk profiles.⁴⁾ Although changes in the 10-year ASCVD risk reflect overall risk management, real-world practice more prioritizes on controlling individual risk factors such as hypertension, diabetes, dyslipidemia, smoking status, physical activity, and obesity. Monitoring the occurrence or resolution of these risk factors is more intuitive for both physicians and patients than tracking changes in the 10-year ASCVD risk scores. Therefore, we aimed to assess the prognostic impact of temporal changes in risk factor status in primary prevention settings.

Data from the National Health Insurance Services (NHIS) Health Screening Cohort of South Korea, a nationwide claims database, were used.^{4,5)} This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital and adhered to the 2013 revised Declaration of Helsinki. Among 1,108,369 individuals who participated in the screening program between 2009 and 2015, we excluded those without repeated screenings at a 4–5 years interval and those without sufficient data to assess changes in risk factors. Additionally, individuals with established ASCVD, malignancy, or end-stage renal disease were excluded. A total of 211,077 individuals were analyzed. The primary outcome was ASCVD events (myocardial infarction, acute coronary syndrome, stable or unstable angina, coronary revascularization, stroke, transient ischemic attack, or peripheral arterial disease) occurring after follow-up screening (4–5 years post baseline screening, until 2019). Changes in risk-factor status between baseline and follow-up screenings were assessed for 6 components: blood pressure (\geq 140/90 mmHg), glycemic control (fasting glucose of \geq 130 mg/dL for diabetic patients; occurrence of diabetes for non-diabetic patients), low-density lipoprotein cholesterol level (\geq 160 mg/dL), smoking status (current smoking), body mass index (\geq 25 mg/kg²), and physical activity. Appropriate physical activity was defined as at least 150 min of moderate-intensity exercise or 75 minutes of weekly vigorous-intensity exercise.¹⁾ To determine the resolution of specific diseases (e.g., hypertension, diabetes, dyslipidemia), we examined claims for diagnostic codes and medications at follow-up screenings. Patients initially diagnosed but lacking these indicators at follow-up prompted further assessment

Goo-Young Cho 
https://orcid.org/0000-0002-7067-5535

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

The authors have no financial conflicts of interest.

Data Sharing Statement

The data generated in this study is available from the corresponding author upon reasonable request.

Author Contributions

Conceptualization: Hwang IC, Kim CH, Choi HM, Yoon YE, Cho GY; Data curation: Hwang IC, Kim JY; Formal analysis: Hwang IC, Kim CH, Kim JY, Park J, Choi HJ; Investigation: Hwang IC, Kim CH, Kim JY, Park J, Choi HJ, Choi HM, Yoon YE, Cho GY; Methodology: Hwang IC, Kim CH, Kim JY, Park J, Choi HJ, Choi HM, Yoon YE, Cho GY; Project administration: Hwang IC; Resources: Hwang IC; Supervision: Hwang IC; Validation: Hwang IC, Yoon YE, Cho GY;

of blood pressure, fasting glucose, and lipid profiles. Resolution was confirmed when diagnostic codes, medications, and screening measurements were all negative at follow-up. Study population was stratified based on the number of risk factors at baseline. Hazard ratios (HRs) for ASCVD events occurring after the follow-up screenings were calculated according to changes in the number of risk factors between baseline and follow-up screenings. Multivariable Cox proportional hazard regression model was used, adjusting for age, sex, smoking status, presence of diabetes, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, and treatment for hypertension. For subgroups with small number of patients, Cox proportional hazard models with Firth’s penalized likelihood procedures were applied. For patients initially presenting with 0, 1, or 2 risk factors, HR was calculated based on the increase in risk factors, using those with the lowest number of risk factors at follow-up as the reference group. Conversely, for patients with 3, 4, or 5–6 risk factors at baseline, HR was calculated based on a decrease in risk factors, with those having the highest number of risk factors at follow-up as the reference group.

Regardless of baseline risk factor status, an increase in risk factors correlated with higher ASCVD event risk, while a decrease corresponded to lower risk (Figure 1). Among individuals without any risk factors at baseline, those with 3 risk factors at follow-up had a higher risk of future ASCVD events (adjusted HR, 2.74; 95% confidence interval, 1.31–5.76), compared to those with no change in risk factor status (no risk factors at both baseline and follow-up examinations). Similar trend was observed among individuals with poor risk factor control at baseline. Compared to those with 5 or 6 risk factors at both baseline and follow-up examinations, individuals with a decrease of 3 risk factors had reduced risk of ASCVD events by nearly 50%.




Figure 1. Associations between changes in risk-factor status and ASCVD events. The risk of ASCVD events is shown according to the increase (left) and decrease (right) in the number of risk factors between baseline and follow-up health screenings. HRs with 95% confidence intervals, calculated using multivariable Cox proportional hazard regression models, are depicted by rhombus marks (◆) for conventional calculation and square marks (■) for Firth’s penalized likelihood procedures. ASCVD = atherosclerotic cardiovascular disease; HR = hazard ratio. *HRs and 95% confidence intervals were unavailable due to the limited number of subjects and events.

Visualization: Hwang IC; Writing - original draft: Hwang IC; Writing - review & editing: Hwang IC, Kim CH, Kim JY, Park J, Choi HJ, Choi HM, Yoon YE, Cho GY.

Several limitations should be acknowledged in this study. Firstly, we relied on a claims database within a population-based cohort, potentially introducing selection bias despite the extensive coverage of the NHIS.⁴⁾⁵⁾ Secondly, we did not assess the impact of medications in our analyses. Thirdly, small sample sizes with rare events in certain subgroups limited statistical significance, even with Firth's penalized likelihood procedures. Finally, it is important to note that each risk factor may carry a different prognostic weight, introducing limitations in our approach.

Nevertheless, this is the first population-based cohort study focusing on the temporal changes in cardiovascular risk factors in primary preventive setting. Unlike calculating changes in 10-year ASCVD risk estimates,⁴⁾ this approach provides practical evidence supporting risk factor control. Specifically, we demonstrated that primary prevention effects can be reflected by changes in risk factor status. Among individuals with appropriate risk factor control at baseline, newly developed risk factors significantly increase ASCVD events risk. Conversely, even in individuals with poor risk factor control at baseline, appropriate management can significantly improve prognosis. These findings emphasize the pivotal prognostic role of managing each risk factor in real-world practice.

ACKNOWLEDGMENTS

We thank Professor Jeong-Ju Yoo, MD, PhD, for her dedication and support of this study.

REFERENCES

1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;140:e596-646. [PUBMED](#) | [CROSSREF](#)
2. Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2018;379:633-44. [PUBMED](#) | [CROSSREF](#)
3. Wright AK, Suarez-Ortegon MF, Read SH, et al. Risk factor control and cardiovascular event risk in people with type 2 diabetes in primary and secondary prevention settings. *Circulation* 2020;142:1925-36. [PUBMED](#) | [CROSSREF](#)
4. Hwang IC, Kim CH, Kim JY, Choi HM, Yoon YE, Cho GY. Rate of change in 10-year atherosclerotic cardiovascular disease risk and its implications for primary prevention. *Hypertension* 2023;80:1697-706. [PUBMED](#) | [CROSSREF](#)
5. Seong SC, Kim YY, Park SK, et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. *BMJ Open* 2017;7:e016640. [PUBMED](#) | [CROSSREF](#)